These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 30275538)

  • 1. Targeting PVR (CD155) and its receptors in anti-tumor therapy.
    Kučan Brlić P; Lenac Roviš T; Cinamon G; Tsukerman P; Mandelboim O; Jonjić S
    Cell Mol Immunol; 2019 Jan; 16(1):40-52. PubMed ID: 30275538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD155 in tumor progression and targeted therapy.
    Zhan M; Zhang Z; Zhao X; Zhang Y; Liu T; Lu L; Li XY
    Cancer Lett; 2022 Oct; 545():215830. PubMed ID: 35870689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD155 as an emerging target in tumor immunotherapy.
    Wu JW; Liu Y; Dai XJ; Liu HM; Zheng YC; Liu HM
    Int Immunopharmacol; 2024 Apr; 131():111896. PubMed ID: 38518596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The N-linked glycosylations of TIGIT Asn
    Lin YX; Hung MC; Hsu JL; Hsu JM
    Biochem Biophys Res Commun; 2021 Jul; 562():9-14. PubMed ID: 34030043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma.
    Lupo KB; Matosevic S
    J Hematol Oncol; 2020 Jun; 13(1):76. PubMed ID: 32532329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.
    Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Zhao X; Yu Y; Zhang H; Xu F; Tian Y
    J Exp Clin Cancer Res; 2021 Aug; 40(1):267. PubMed ID: 34433460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy.
    Mu Y; Guan X
    Curr Med Chem; 2024; 31(13):1634-1645. PubMed ID: 38666504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD155 and Its Receptors as Targets for Cancer Therapy.
    Paolini R; Molfetta R
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT.
    Zhou X; Du J; Zhou X; Niu X; Li W; Chen C; Lv S; Wu A; Gou S; Sun Y; Zhai W; Qiu L; Qi Y; Zhao W; Gao Y
    Cell Commun Signal; 2021 Feb; 19(1):12. PubMed ID: 33557880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the "PVR-TIGIT axis" with immune checkpoint therapies.
    Gorvel L; Olive D
    F1000Res; 2020; 9():. PubMed ID: 32489646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
    Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD155, an onco-immunologic molecule in human tumors.
    Gao J; Zheng Q; Xin N; Wang W; Zhao C
    Cancer Sci; 2017 Oct; 108(10):1934-1938. PubMed ID: 28730595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD155: A Key Receptor Playing Diversified Roles.
    Nandi SS; Gohil T; Sawant SA; Lambe UP; Ghosh S; Jana S
    Curr Mol Med; 2022; 22(7):594-607. PubMed ID: 34514998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.
    Boissière-Michot F; Chateau MC; Thézenas S; Guiu S; Bobrie A; Jacot W
    Front Immunol; 2022; 13():1058424. PubMed ID: 36544779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering.
    Stengel KF; Harden-Bowles K; Yu X; Rouge L; Yin J; Comps-Agrar L; Wiesmann C; Bazan JF; Eaton DL; Grogan JL
    Proc Natl Acad Sci U S A; 2012 Apr; 109(14):5399-404. PubMed ID: 22421438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT.
    Diong SJ; Jashnani A; Drake AW; Bee C; Findeisen F; Dollinger G; Wang F; Rajpal A; Strop P; Lee PS
    MAbs; 2023; 15(1):2253788. PubMed ID: 37675979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
    Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
    J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
    Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.